Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Eniola Odetunde/Axios

How sick a person gets from a virus can depend on how much of the pathogen that person was exposed to and how much virus is replicating in their body — questions that are still open for the novel coronavirus.

Why it matters: As people try to balance resuming parts of their daily lives with controlling their risk of COVID-19, understanding the role of viral load could help tailor public health measures and patient care.

Driving the news: An analysis of 5,000 genomic sequences of the coronavirus from patients found those infected with a now-dominant strain with a specific mutation "had higher loads of virus in their upper respiratory tracts, a potential factor in making the strain spread more effectively," the Washington Post reports.

  • Viruses typically mutate as they spread through a population, and the mutation that is accumulating wasn't linked to the virus becoming deadlier, according to the study, which hasn't yet been peer-reviewed.
  • But the research underscores open questions about COVID-19: How does the amount of virus in someone affect transmission to others, and the severity of the disease?

How it works: Viral dose is how much virus someone is exposed to when they are infected. Viral load is the amount of virus produced in someone's body after they are infected.

  • A higher infectious dose of a virus and a higher viral load are linked to more severe disease from influenza, poxviruses and other viruses.

For SARS-CoV-2, the virus that causes COVID-19, "there's accumulating data on both sides of the equation," Monica Gandhi, a professor of medicine and an infectious disease doctor at UCSF, tells Axios.

  • In a study of Syrian hamsters, for example, those infected with a higher dose of SARS-CoV-2 had worse outcomes than those with smaller amounts, supporting an earlier study on hamsters checking if "masks" helped prevent transmission, she points out.
  • Outbreak investigations show that where there's universal masking of a population, the severity of disease goes down.
  • Some researchers suggest a decline in death rate and the rise in asymptomatic cases in the U.S. this summer — both coming at a time when mask-wearing became more common — indicate reducing the dose of the virus may reduce the severity of disease.

"It's very interesting that it seems like it's correlating with masking, this lower rate of severe illness," says Gandhi, adding that the hypothesis remains unproven but has some growing evidence behind it.

  • She co-authored a perspective piece in the NEJM this week that says universal adoption of masks could reduce infections and severity until an effective vaccine is distributed.
  • Last week, CDC director Robert Redfield suggested face masks are "more guaranteed" to offer protection against the coronavirus than a potential vaccine.

What's happening: Evidence is emerging about the link between viral load and how severe COVID-19 is for a patient.

  • In a study of more than 3,000 patients in three New York City hospitals, nearly 40% who tested positive for COVID-19 and had a high viral load died in the hospital.
  • But the risk of dying was lower — dropping to about 15% — for patients with a low viral load, Michael Satlin, an infectious disease specialist at Weill Cornell Medicine and NewYork-Presbyterian, and colleagues reported last week in the journal Cancer Cell.
  • Of note: The study was done at the height of the city's outbreak in the spring, and Satlin says that given improvements in caring for patients with COVID-19, he wouldn't expect to see such high mortality rates today.
  • And the amount of virus the patients were exposed to or their viral load when symptoms started wasn't known — connecting those dots will require more testing, he adds.

Yes, but: Other studies have also found some people without symptoms can have viral loads similar to those with symptoms. And children, who tend to be spared severe COVID-19 complications, can carry as much or more of the virus in their upper respiratory tract.

  • "Viral load is a part of the picture, but it's not the full picture," infectious disease specialist Ravina Kullar told MedPage Today, adding that disease severity depends on a person's immune system.

What to watch: Knowing a patient's viral load could be helpful to providers in determining how therapies should be directed.

  • Viral load information is in the PCR tests done to confirm SARS-CoV-2 infection but the tests aren't approved by the FDA for that quantitative information, Satlin says.
  • If it could be released to clinicians, "it could be very useful" for determining care for people who are hospitalized, he adds.

Go deeper: Where the science stands on using face masks against coronavirus

Go deeper

Updated 8 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: FDA approves Pfizer boosters for high-risk individuals, people 65 and up — Team USA to mandate vaccine for Winter Olympic hopefuls — U.S. to buy 500 million more Pfizer doses to share with the world.
  2. Health: Some experts see signs of hope as cases fall — WHO: Nearly 1 in 4 Afghan COVID hospitals shut after Taliban takeover — D.C. goes further than area counties with vaccine mandates.
  3. Politics: Bolsonaro isolating after health minister tests positive at UN summit — United Airlines says 97% of U.S. employees fully vaccinated — Mormon Church to mandate masks in temples.
  4. Education: Asymptomatic Florida students exposed to COVID no longer have to quarantine — Education Department investigating Texas mask mandate ban — D.C. schools to require teachers, staff to receive vaccine without testing option.
  5. Variant tracker: Where different strains are spreading.

Jan. 6 select committee subpoenas four Trump aides

Photo: Alex Wong/Getty Images

The Jan 6. select committee investigating the deadly Capitol riot has subpoenaed four aides to former President Trump for testimony and documents.

Why it matters: Former White House chief of staff Mark Meadows, former communications official Dan Scavino, former Defense Department official Kash Patel, and former Trump advisor Steve Bannon were all in touch "with the White House on or in the days leading up to the January 6th insurrection," the committee said in a release.

U.S. friends in Latin America are turning to China

Illustration: Shoshana Gordon/Axios

The U.S. is losing Latin America to China without putting up a fight, Ecuador’s ambassador to Washington told Axios, laying bare her frustrations with early inattention from the Biden administration.

Why it matters: Ecuador isn't alone. China has deepened its engagement in the region, and it's now the top trading partner for many of the region's largest economies. That gives Beijing considerable leverage in a region historically dominated by the U.S., and makes Latin America a major frontier in the global competition for influence.